Autoimmune Hemolytic Anemia

Howard A Liebman; Ilene C Weitz

doi:10.1016/j.mcna.2016.09.007

Autoimmune Hemolytic Anemia

Med Clin North Am. 2017 Mar;101(2):351-359. doi: 10.1016/j.mcna.2016.09.007. Epub 2016 Dec 14.

Authors

Howard A Liebman¹, Ilene C Weitz²

Affiliations

¹ Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: liebman@usc.edu.
² Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

PMID: 28189175
DOI: 10.1016/j.mcna.2016.09.007

Abstract

Autoimmune hemolytic anemia is an acquired autoimmune disorder resulting in the production of antibodies directed against red blood cell antigens causing shortened erythrocyte survival. The disorders can present as a primary disorder (idiopathic) or secondary to other autoimmune disorders, malignancies, or infections. Treatment involves immune modulation with corticosteroids and other agents.

Keywords: Anemia; Autoantibodies; Hemolysis.

Publication types

Review

MeSH terms

Anemia, Hemolytic, Autoimmune / diagnosis
Anemia, Hemolytic, Autoimmune / immunology*
Anemia, Hemolytic, Autoimmune / therapy
Hematologic Tests
Humans
Immunosuppressive Agents / therapeutic use
Splenectomy

Substances

Immunosuppressive Agents